1
|
AlKharboush H, Alshehri F, Alatwi I, Al Karni K, Alatawi A, Hamdan AM. The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients. Cureus 2020; 12:e11895. [PMID: 33415047 PMCID: PMC7781860 DOI: 10.7759/cureus.11895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/04/2020] [Indexed: 11/05/2022] Open
Abstract
Background and objective Anemia is a common prognosis of chronic kidney disease (CKD). It is predominantly managed with synthetic erythropoietin. The principal objective of this study was to compare the cost-effectiveness of the use of short-acting erythropoietin with the long-acting one to maintain serum hemoglobin (Hb) concentration within the range of 10.5-12 g/dL. Method This was a retrospective cohort study involving patients diagnosed with stage 5 CKD according to the Saudi Society of Nephrology and Transplantation conducted at eight tertiary care centers in the Tabuk region, Saudi Arabia. We compared the cost-effectiveness of long-acting erythropoietin with the short-acting one. The decision analysis model and Markov model were established to simulate a cohort of 55-year-old patients to estimate the incremental cost and quality-adjusted life-year (QALY) for chronic hemodialysis patients (CHP) treated with either darbepoetin-alfa or epoetin-beta for at least nine months. The incremental cost per QALY was the main outcome marker for using both medications. Serum HB levels were monitored on a monthly basis and costs were calculated. Results A total of 291 CHP met our inclusion criteria; 194 of them were treated with darbepoetin-alfa while 97 were treated with epoetin-beta. The mean age was 56.3 ± 11.2 years for the darbepoetin-alfa group and 55.2 ± 7.8 years for the epoetin-beta cohort. The baseline serum Hb was 10.68 ± 0.98 g/dL for darbepoetin-alfa patients and 11.63 ± 0.32 g/dL for the epoetin-beta group (p=0.003). We observed a significant difference between the percentage of patients successfully treated with epoetin-beta and those managed with darbepoetin-alfa (80.4% vs. 63.92%, p=0.01) with considerably less cardiovascular side effects. The average annual cost per patient was estimated at $919.47 and $12,319.41 for epoetin-beta and darbepoetin-alfa respectively. Also, the average effectiveness was 0.58 for darbepoetin-alfa vs. 0.61 for epoetin-beta. The average cost-effectiveness ratio was $980.25 and $15,023.66 with an incremental cost difference of -$966 in favor of epoetin-beta compared to darbepoetin-alfa. Conclusion Based on our findings, treating anemia in hemodialysis patients using epoetin-beta is very cost-effective compared to managing them with darbepoetin-alfa.
Collapse
Affiliation(s)
- Hanan AlKharboush
- Pharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk, SAU
| | - Fatimah Alshehri
- Pharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk, SAU
| | - Ibrahim Alatwi
- Pharmaceutical Care Administration, General Directorate of Health Affairs in Tabuk Region, Ministry of Health, Saudi Arabia, Tabuk, SAU
| | - Khaled Al Karni
- Department of Pharmaceutical Care, King Khaled Civil Hospital, Tabuk, SAU
| | - Abdurahman Alatawi
- Pharmaceutical Care Administration, General Directorate of Health Affairs in Tabuk Region, Ministry of Health, Saudi Arabia, Tabuk, SAU
| | - Ahmed M Hamdan
- Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, SAU
| |
Collapse
|
2
|
Economic Evaluation of Severe Anaemia: Review-Based Recommendations and a Conceptual Framework. EUROPEAN MEDICAL JOURNAL 2020. [DOI: 10.33590/emj/20-00102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Objective: Novel anaemia treatments have greatly improved patient outcomes in the last decade and have also undergone economic evaluations in various settings using heterogenous model structures, costs, and inputs. The objectives were to review published economic evaluation studies in major red blood cell disorders, identify limitations in the applied methodology, provide a set of recommendations, and produce a conceptual framework for future economic research in this disease area.
Methods: A targeted search was conducted for economic literature evaluating treatments in major red blood cell disorders related to anaemia. Disorders included autoimmune haemolytic anaemia, β-thalassaemia, chemotherapy-induced anaemia, anaemia in chronic kidney disease, and severe aplastic anaemia. Budget impact models and cost-effectiveness and cost-utility analyses were considered. Modelling assumptions regarding the model structure, time horizon, perspective, and type of costs were reviewed and recommendations and a conceptual framework for future economic analyses were created.
Results: A total of four budget impact models, nine cost-utility analyses, and four cost-effectiveness analyses were investigated. A major limitation was that the included costs varied significantly across studies. Costs which were rarely included, and generally should be considered, were related to adverse events, mortality, and productivity. Additionally, relationships between levels of serum ferritin, hepatic or total body iron, and haemoglobin with long-term complications and mortality were rarely included.
Conclusion: Published economic analyses evaluating treatments for major red blood cell disorders frequently exclude vital costs. A set of recommendations and a conceptual framework will aid researchers in applying a more comprehensive approach for economic evaluations in major red blood cell disorders.
Collapse
|
3
|
Brenner N, Kommalapati A, Ahsan M, Ganguli A. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. J Nephrol 2019; 33:267-275. [PMID: 31782127 DOI: 10.1007/s40620-019-00680-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Accepted: 11/24/2019] [Indexed: 01/28/2023]
Abstract
Anemia is a major complication of chronic kidney disease (CKD) that leads to many symptoms of this disease and worsens cardiovascular health. Treatment of this condition was revolutionized three decades ago by the commercial availability of recombinant human erythropoietin which held the promise of completely eliminating the need for red blood cell transfusion (RBCT). Despite specific therapy now available for anemia in CKD, clinical data accumulated in the last 2 decades suggests that there is a continued need for RBCT, which, we surmise, is due to underutilization of Erythropoietin Stimulating Agents (ESA) or clinical settings such as active bleed, bone marrow resistance such as myelofibrosis or infections where ESAs are ineffective. The purpose of this narrative review is to highlight the adverse effects and summarize the current patterns of RBCT use in all stages of CKD while elaborating on the clinical characteristics of patients that increases their risks of transfusion exposure. We discuss, briefly, salient features of the pathophysiology of anemia in CKD and its contemporary therapies while presenting our perspectives on how to optimize transfusion strategies without compromising patient safety.
Collapse
Affiliation(s)
- Nicole Brenner
- Division of Nephrology, Department of Medicine, Georgetown University/Washington Hospital Center, 110 Irving Street, Suite 2A 50, Washington, DC, NW, 20010, USA
| | | | - Muhammad Ahsan
- Division of Nephrology, Department of Medicine, Georgetown University/Washington Hospital Center, 110 Irving Street, Suite 2A 50, Washington, DC, NW, 20010, USA
| | - Anirban Ganguli
- Division of Nephrology, Department of Medicine, Georgetown University/Washington Hospital Center, 110 Irving Street, Suite 2A 50, Washington, DC, NW, 20010, USA.
| |
Collapse
|
4
|
Chacón-Araya M, Rey-Rodríguez D, Rodríguez De León F, Ramos-Esquivel A, Sunning T. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study. J Med Econ 2019; 22:736-741. [PMID: 30915883 DOI: 10.1080/13696998.2019.1600527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Objectives: There is a lack of data in Panama on the potential differences in total healthcare professional (HCP) time between routine administrations of short-acting erythropoietin simulating agents (ESAs) (i.e. epoetin alfa) and continuous erythropoietin receptor activator (CERA) (i.e. methoxy polyethylene glycol-epoetin beta). This study aimed to quantify the HCP time associated with a single administration of epoetin alfa and CERA for the treatment of anemic patients with chronic kidney disease (CKD) on hemodialysis. Methods: This was a multi-center, cross-sectional study, using a time-and-motion methodology. Costs related to HCP time and consumables usage associated with administration of epoetin alfa and CERA were estimated. Results: Based on 60 administrations of either CERA or epoetin alfa, the estimated savings in mean total active HCP time were 2.34 (95% confidence interval = 1.87-2.81) min (-30%) per administration. When extrapolating to a full year's treatment with intravenous ESA, it would require a total of 20.3 (95% CI = 19.90-20.71) h of HCP time for epoetin alfa vs 1.1 (95% CI = 1.01-1.19) h for CERA per patient per year. Estimated savings in active HCP time per patient per year were 19.20 (95% CI = 19.20-19.21) h (-95%). This, in turn, translates into staff cost efficiency that favors Mircera with an estimated annual saving of $78.24 (95% CI = 78.24-78.28) (-95%) per patient. Conclusions: Data from a real-world setting showed that the adoption of CERA could potentially lead to a reduction in active HCP time. Highlights Few comparative data have explored the costs and potential savings of using long-acting erythropoietin-stimulating agents (ESA) instead of short-acting ESAs to treat anemia in CKD patients on hemodialysis. This time-and-motion study shows that use of CERA reduces total healthcare professional time and could represent a save for an institution in a real-world setting in Panama.
Collapse
Affiliation(s)
| | | | | | - Allan Ramos-Esquivel
- d Department of Pharmacology School of Medicine , University of Costa Rica , San José , Costa Rica
| | - Tao Sunning
- e United BioSource Corporation , Montreal , Canada
| |
Collapse
|
5
|
Ahmed S, Bughio S, Hassan M, Lal S, Ali M. Role of Ultrasound in the Diagnosis of Chronic Kidney Disease and its Correlation with Serum Creatinine Level. Cureus 2019; 11:e4241. [PMID: 31131164 PMCID: PMC6516621 DOI: 10.7759/cureus.4241] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Objective: We aimed to study the role of ultrasound in the diagnosis of chronic kidney disease (CKD) and its correlation with serum creatinine level. Materials and methods: This was a retrospective cross sectional study conducted in the ultrasound department of Dr. Ziauddin Hospital Clifton campus, Karachi from April 6, 2017 to October 6, 2017 for a period of six months. A total of 200 patients with CKD and glomerular filtration rate (GFR) determined to be < 60 ml/min were included in this study. Blood tests were gathered from the chosen patients, serum creatinine estimation was done for those patients and they underwent ultrasonography on the same day to assess echogenicity, parenchymal thickness, cortical thickness, and longitudinal length. This information was noted in the pro forma. Results: The average age of the patients was 54.62±13.3 years. Mean serum creatinine was significant among echogenicity grades [p=0.0005]. Mean parenchymal thickness was also significant among echogenicity grades (p=0.0005). Mean longitudinal length was also significant among echogenicity grades (p=0.0005). Mean corticomedullary distinction was also significant among echogenicity grades (p=0.0005). A statistically significant highly positive correlation was observed between serum creatinine and cortical echogenicity grading (r=0.915 P = 0.0005). Conclusion: The best sonographic parameter that correlates with serum creatinine is renal cortical echogenicity and its grading in comparison to longitudinal length, parenchymal thickness, and cortical thickness in patients of CKD. Since renal cortical echogenicity has the advantage of being irreversible in comparison to serum creatinine levels, it can be used as a parameter of renal function.
Collapse
Affiliation(s)
- Shakeel Ahmed
- Urology, Sindh Institute of Urology and Transplantation, Karachi, PAK
| | | | | | - Sajan Lal
- Radiology, Dr. Ziauddin Hospital, Karachi, PAK
| | | |
Collapse
|
6
|
Darsonval A, Besson V, Cavalin C. Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study. PHARMACOECONOMICS - OPEN 2017; 1:223-229. [PMID: 29441494 PMCID: PMC5691838 DOI: 10.1007/s41669-017-0016-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE This study aimed to assess the cost impact of administering erythropoiesis-stimulating agents once every 4 weeks instead of one to three times a week to treat anaemia in patients undergoing dialysis. METHODS This was a monocentric retrospective study involving 27 patients who underwent haemodialysis between 2009 and 2013 in a university hospital in Angers, France. The study was a cost-minimisation analysis from the hospital perspective. Only direct medical costs were considered. RESULTS This study demonstrated that therapeutic management of anaemia with methoxy polyethylene glycol-epoetin beta would save medical and nurse time (7 days and 15 days per year, respectively) and reduce costs by €59,960 a year for an active file of 40 patients undergoing haemodialysis, assuming a 100% occupancy rate in the above-mentioned hospital. CONCLUSION This study indicated that treating anaemia by administering erythropoiesis-stimulating agents once every 4 weeks instead of one to three times a week in patients undergoing haemodialysis would be beneficial for the hospital.
Collapse
Affiliation(s)
- Astrid Darsonval
- Service Pharmacie, Centre Hospitalier Universitaire, 49100, Angers, France.
| | - Virginie Besson
- Service Hémodialyse, Centre Hospitalier Universitaire, 49100, Angers, France
| | - Claire Cavalin
- Cellule d'évaluation médico économique, GIRCI Grand Ouest, Tours, France
| |
Collapse
|